What is he best known for?
The fields of study he is best known for:
Ali Shilatifard focuses on Genetics, Histone methyltransferase, Histone code, Histone methylation and Cell biology.
His work is connected to Histone, Chromatin, Regulation of gene expression, Methylation and Epigenetics, as a part of Genetics.
His studies deal with areas such as Histone H2B, Histone H2A, Epigenomics and Histone H3 as well as Histone methyltransferase.
He studied Histone H2A and Histone H1 that intersect with Histone octamer.
His work carried out in the field of Cell biology brings together such families of science as RNA, Non-coding RNA, Chromatin immunoprecipitation, DNA-binding protein and RNA polymerase I.
His Histone H2B ubiquitination research focuses on Molecular biology and how it relates to RNA polymerase II.
His most cited work include:
- Global landscape of protein complexes in the yeast Saccharomyces cerevisiae (2539 citations)
- An operational definition of epigenetics (1169 citations)
- Chromatin Modifications by Methylation and Ubiquitination: Implications in the Regulation of Gene Expression (917 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Cell biology, Chromatin, Genetics, Histone and Molecular biology.
His Chromatin research is multidisciplinary, relying on both Regulation of gene expression, Transcription factor, Epigenetics and Computational biology.
Ali Shilatifard focuses mostly in the field of Histone, narrowing it down to topics relating to Cancer research and, in certain cases, Leukemia.
His research integrates issues of RNA polymerase II and Mutant, Drosophila Protein in his study of Molecular biology.
His study in Histone H3 is interdisciplinary in nature, drawing from both Demethylase, Histone code, Histone H2A, Histone H1 and Histone methylation.
His Histone methyltransferase research is multidisciplinary, incorporating elements of Histone H2B and Histone octamer.
He most often published in these fields:
- Cell biology (34.20%)
- Chromatin (30.94%)
- Genetics (28.66%)
What were the highlights of his more recent work (between 2018-2021)?
- Chromatin (30.94%)
- Cell biology (34.20%)
- Histone (27.36%)
In recent papers he was focusing on the following fields of study:
Chromatin, Cell biology, Histone, Cancer research and Transcription are his primary areas of study.
His Chromatin study combines topics in areas such as Transcription factor, Gene expression, Transcriptional regulation, Leukemia and Computational biology.
His research in Cell biology intersects with topics in Regulation of gene expression, Protein subunit, Methyltransferase and DNA methylation.
His Histone study combines topics from a wide range of disciplines, such as Mutation and Epigenetics.
The Transcription study combines topics in areas such as Promoter, RNA polymerase II and Messenger RNA.
Gene is a subfield of Genetics that Ali Shilatifard explores.
Between 2018 and 2021, his most popular works were:
- Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. (362 citations)
- Epigenetic modifications of histones in cancer (77 citations)
- Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. (44 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Chromatin, Cell biology, Histone, Regulation of gene expression and Histone H3.
His study with Chromatin involves better knowledge in Gene.
The concepts of his Cell biology study are interwoven with issues in Cellular differentiation, SWI/SNF, Chromatin remodeling, RNA polymerase II and Gene targeting.
His Histone research includes elements of Cancer research and Epigenetics.
His Regulation of gene expression research incorporates elements of Cleavage, Methylation and DNA methylation.
His Histone H3 research integrates issues from Radiosensitizer and Methyltransferase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
